Biocon Biologics Ltd, a wholly-owned subsidiary of Biocon Ltd, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending marketing authorisation for its Pertuzumab biosimilar, Pebrilzo, for the treatment of HER2-positive breast cancer. The product, available as a 420 mg concentrate solution for […]